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Abstract: To examine the effect of sildenafil on erectile dysfunction (ED) and psychosocial 
outcomes in alcohol-dependent (AD) men, 108 men with these diagnoses were randomly 
assigned to either take sildenafil (50 mg) as add-on to standard treatment for AD, or the 
same treatment without sildenafil, for 12 weeks. Only 50 patients in sildenafil group and 51 in 
control  group  twice  completed  the  International  Index of Erectile Function (IIEF) and a 
battery of self-report questionnaires. IIEF scores and psychosocial functioning, self-esteem 
and support from friends improved only for sildenafil-treated patients (P < 0.001). The high 
effect sizes suggest that the observed benefits are unlikely to be a placebo effect, although 
their unspecific nature could not be ruled out. In men with ED associated with AD, sildenafil 
improves  both  ED  and  psychosocial outcomes.  Further placebo-controlled clinical trial is 
warranted. 
Keywords:  alcohol  dependence;  erectile  dysfunction;  sildenafil;  depression;  functioning;  
self-esteem; social support 
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Abbreviations: ED = erectile dysfunction; AD = alcohol dependence; IIEF = International 
Index of Erectile Function; PTSD = Post Traumatic Stress Disorder; AASD = Alcohol-
associated  sexual  dysfunction;  GLF  =  Global  Life  Functioning  inventory;  BDI  =  Beck 
Depression  Inventory;  RGSES  =  Rosenberg’s  General  Self-Esteem  Scale:  
MSPSS = Multidimensional Scale of Perceived Social Support; SD = standard deviations; 
ES = effect size. 
  
 
1. Introduction 
 
Alcohol dependent men commonly suffer from erectile dysfunction (ED) [1-4], and conversely, men 
having  ED  are  frequently  chronic  alcohol  addicts  [5,6].  Particularly  those  in  remission,  who  were 
forcibly withdrawn from alcohol, often complain about impotence and report it as a “cause” for relapse. 
Findings from previous research show that alcohol increasingly inhibits normal erectile function [7] and 
it, in turn, may lead to greater alcohol consumption as a “self-treatment” attempt. Thus, the vicious 
cycle of ED and heavy alcohol consumption is developed. 
Sildenafil  citrate  (VIAGRA
®)
  is  reportedly  an  effective  and  safe  medication  indicated  for  the 
treatment of ED [8,9]. It is a competitive inhibitor of cGMP-specfic phosphodiesterase type 5. The 
medication  amplifies  the  effect  of  sexual  stimulation  by  retarding  the  degradation  of  this  enzyme. 
Sildenafil was found effective in several subpopulations of men with ED, including those suffering from 
diabetes  [10,11],  hypertension  [12,13],  spinal  cord  injuries  [14-17],  multiple  sclerosis  [18],  
depression [20-24], post traumatic stress disorder [25], schizophrenia [26,27], those after resection of 
the prostate or radical prostatectomy [28],
 renal transplantation [29], dialytic treatment [30], and those 
aged 65 years and older [31,32]. Efficacy has been maintained for up to one year with no evidence of 
tolerance [19].  
Adverse  events  associated  with  sildenafil  use  have  generally  been  transient  and  have  
mild-to-moderate  severity.  Primarily  they  are  related  to  the  drug’s  vasodilator  properties  and  were 
reported to occur in nearly 10% of patients in clinical trials  [33-36]. The most commonly reported 
adverse events associated with sildenafil use were: headache (16%), flushing (10%), dyspepsia (7%), 
and nasal congestion (4%). Drug interactions with sildenafil are minimal, yet its use is contraindicated in 
those receiving nitrates in any form. Regarding the interaction with alcohol, some evidence of the safety 
of  such  combination  was  recently  reported.  In  a  double-blind,  randomized,  crossover  study  of  the 
effects of sildenafil in doses of 50 mg co-administered with alcohol in 12 healthy subjects, no significant 
hemodynamic or pharmacokinetic interactions between the two were observed (Pfizer Inc., personal 
communication, 2002). However, the hemodynamic changes that occurred during sexual intercourse 
may be magnified by the consumption of alcohol that requires great caution in the co-administration of 
sildenafil and alcohol.  
Findings  from  several  studies  support  a  biopsychosocial  formulation  of  alcoholics’  sexual  
problems  [1,2].  This  approach  suggests  that  marital conflict is a major contributing factor to most 
sexual problems of alcoholics, apart from the direct physical effects of acute and chronic alcohol intake 
on the elevated rates of impotence. Therefore, taking into consideration the sensitivity of alcoholics to Int. J. Environ. Res. Public Health 2009, 6                 
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interpersonal relationships, variables closely related to their marital relationships, such as depression 
symptoms,  psychosocial  functioning,  social  support  and  self-esteem,  would  be  investigated  as  the 
additional indicators of the sildenafil treatment efficacy.  
In our recent preliminary, uncontrolled, open-label study we have demonstrated the beneficial effects 
of sildenafil treatment on sexual function, quality of life and emotional distress in 50 alcohol dependent 
patients [37]. In the present report, in open-label, multicenter, parallel-group design we evaluated the 
efficacy of sildenafil treatment in the same population in comparison to untreated control group, with 
regard to depression, psychosocial functioning, social support and self-esteem in addition to its effect on 
sexual  function.  We  hypothesizes  that  the  beneficial  effect  of  sildenafil  citrate  on  ED  in  alcohol 
dependent men is associated also with improvement in these psychosocial outcomes.  
 
2. Method 
 
2.1. Study Design 
 
This was a multicenter, prospective, parallel group, randomized, open-label, flexible dose study. It 
was  a  12-week  trial  conducted  simultaneously  at  11  outpatient  medical  centers  for  alcohol  abuse 
treatment across Israel from January 1, 2005 to June 31, 2006. All centers belong to the Israeli Ministry 
of Health, and are audited by the Department for the Treatment of Addictions. The Ministry of Health 
institutional  review  board  approved  the  study  protocol,  and  all  patients  provided  written  informed 
consent prior to participating in the study. 
 
2.2. Patients 
 
Similar to our preliminary report [37], male patients were eligible if they met the following inclusion 
criteria: 1) were between ages 18 and 50 years; 2) had a ICD-10 diagnosis of AD (F10.2); 3) sought 
treatment with the aim to stop alcohol consumption; 4) completed a detoxification program not later 
than the one month preceding the study recruitment; 5) had complaints of ED for at least 12 weeks 
preceding the study; and 6) had a regular female partner for the study duration.  
AD was diagnosed according to International Classification of Diseases, Tenth Edition  (ICD-10) 
criteria  [38]  adopted  in  Israel  since  1994.  The  alcohol  history  was  described  by  the  following 
parameters: 1) age at first alcohol consumption, 2) age at first binge, 3) duration of harmful alcohol 
consumption, 4) number of prior inpatient or outpatient detoxifications, 5) average alcohol intake in last 
six months (gram alcohol/drinking day), and 6) number of drinking days during last month. The severity 
of AD was evaluated according to ICD-10 criteria for three categories according to the frequency of 
drinking  (during  the  previous  6  months)  and amount of alcohol intake. These were: 1) continuous 
drinkers = (almost) daily alcohol consumption without binges; 2) frequent heavy drinkers = frequent 
alcohol consumption (more than 3 days/week) with frequent intoxication (more than one/week); and 3) 
episodic drinkers = less frequent, irregular alcohol consumption with longer (>5 days) sober periods, 
and some binges (less than one/week). Int. J. Environ. Res. Public Health 2009, 6                 
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Alcohol-associated sexual dysfunction (AASD) was defined by carefully elaborated DSM-IV criteria 
for alcohol-induced sexual dysfunction [39], which includes specific items for impaired desire, arousal 
(ED), orgasm, and sexual pain. Patients had to have substantial impaired sexual function that caused 
significant distress, defined by at least one of the following criteria: ED as defined by persistent or 
recurrent inability to attain an adequate erection until completion of sexual activity; inability to have an 
orgasm, or ejaculatory delay of at least 10 minutes for masturbation or intercourse. 
Patients  were  not  enrolled  if  they  had  anatomical  penile  deformities  (e.g.,  Peyronie’s  disease), 
primary or prior diagnosis of a sexual disorder other than AASD, co-morbid serious medical illnesses 
(hepatic,  renal,  neurological,  cardiovascular,  hematological,  diabetes  mellitus),  suicide  risk,  acute 
psychosis, severe depression (with psychotic features), organic brain syndromes or current use of other 
than  alcohol  psychoactive  substances,  drugs  or  therapies,  such  as  benzodiazipines,  sedatives, 
antidepressants,  barbiturates,  and  antipsychotics.  The  psychiatric  diagnostic  assessments  were  made 
according to ICD-10 criteria. 
 
Figure 1. Flow of patients through the trial. 
 
 
2.3. Study Protocol 
 
Patients  were  enrolled  during  1.5  years  and  recruited  from  outpatient  settings  and  referrals.  All 
patients were evaluated for eligibility at screening (N = 127) (Figure 1) and all consenting patients  
(N = 108) completed the International Index of Erectile Function (IIEF) [40] to establish their ability 
for self-evaluation of sexual dysfunction. All patients received a physical examination, including blood 
pressure, electrocardiogram, and standard biochemistry tests (blood urea nitrogen, uric acid, glucose, 
total protein, albumin, total bilirubin, total cholesterol, triglycerides, fibrinogen, alkaline phosphatase, 
SGOT, SGPT, sodium, potassium, chloride, calcium, inorganic phosphorus, bicarbonate, creatinine, and Int. J. Environ. Res. Public Health 2009, 6                 
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creatine phosphokinase [CPK]) and hematological laboratory tests (hemoglobin, hematocrit, erythrosyte 
count, white blood cell count [WBC], total and differential WBC count, and platelet count).  
Using a random number generator for each incoming participant for treatment decision-making [41], 
a computer-generated randomization schedule was developed. This resulted in 54 patients assigned to 
sildenafil citrate as add-on to standard ongoing outpatient program for treatment of AD and another 54 
patients assigned to only the standard program without sildenafil. This program involved education and 
therapy, addressing problems contributing to or resulting from the alcoholism, and learning skills to 
manage the alcoholism over time. The only restriction to this randomization was that the groups be of 
equal size. The largest difference in numbers assigned to the two groups at endpoint of the study was 3. 
Additionally, there were no statistically significant differences between assigned groups at baseline in 
socio-demographic characteristics (Table 1). At baseline, eligible patients randomly assigned to receive 
sildenafil were instructed to take one tablet approximately one hour before anticipated sexual activity 
but not more than once daily. They were also instructed to make at least two attempts at sexual activity 
weekly. The dose of the drug could be adjusted from 1 to 2 tablets (VIAGRA
® was provided by Pfizer 
Pharmaceuticals  Israel  Ltd,  Herzliya  Pituach,  Israel).  Drug  accountability  and  self-rated  and  
physician-rated assessments were performed at baseline and 12 weeks later. Throughout the study, the 
investigators monitored and collected any spontaneous reports of adverse events and evaluated their 
severity and relationship to the study medication.  
 
Table 1. Sociodemographic characteristics and alcohol history. 
Variable  Sildenafil group (n = 50)  Control group (n = 51)   
Age (yr.)   44.0 (8.7)  43.5 (5.9)  t = 0.37, df = 99, P = 0.71 
Marital status 
 Single  6 (12)  2 (3.9)  χ²  = 4.57, df = 2, P = 0.12 
 Married  31 (62)  41 (80.4)   
 Divorced/separated/Widowed  13 (26)  8 (15.7)   
Education (yr.)  11.1 (4.5)  10.2 (3.5)  t = 1.08, df = 99, P = 0.33 
Employment status       
 Employed  16 (32.0)  16 (31.4)  χ²  = 0.005, df = 1, P = 1.0 
 Unemployed  34 (68.0)  35 (68.6)   
Religious affiliation       
 Jewish  31 (62.0)  34 (66.7)  χ²  = 0.24, df = 1, P = 0.70 
 Non-Jewish  19 (38.0)  17 (33.3)   
Immigration status       
  Non-immigrant  23 (46.0)  38 (74.5)  χ²  = 8.58, df = 1, P = 0.004 
  Immigrant  27 (54.0)  13 (25.5)   
Length of immigration (yr.)  16.4 (13.3)  18.1 (15.4)  t = 0.42, df = 51, P = 0.68 
Age at first alcohol 
consumption (yr.) 
17.2 (3.4)  21.3 (7.0)  t = 3.75, df = 99,  
P < 0.001 
Age at first binge (yr.)  20.5 (6.4)  26.1 (8.6)  t = 3.68, df = 99,  
P < 0.001 
Duration of harmful alcohol 
consumption (yr.) 
14.8 (9.7)  13.0 (10.4)  t = 0.91, df = 99, P = 0.36 Int. J. Environ. Res. Public Health 2009, 6                 
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Table 1. Cont. 
No. of prior inpatient 
detoxification(s) 
     
 0  30 (60.0)  28 (54.9)  χ²  = 0.35, df = 2, P = 0.81 
 1  13 (26.0)  14 (27.5)   
 2+  7 (14.0)  9 (17.6)   
Average alcohol intake in last 6 
months (g alcohol/drinking 
day) 
700 (648.8)  694 (453.8)  t = 0.048, df = 99, P = 0.96 
No. of drinking days in last 
month 
8.6 (10.8)  6.8 (10.3)  t = 0.85, df = 99, P = 0.43 
Mean scores ±  SD are shown, if other not indicated. 
 
2.4. Outcome Measures 
 
Efficacy was evaluated using a battery of validated measurements. These included the IIEF [40], the 
Global Life Functioning inventory (GLF) [42], Beck Depression Inventory-short form (BDI-13) [43], 
General Self-Esteem Scale (RGSES) [44], and the Multidimensional Scale of Perceived Social Support 
(MSPSS) [45]. Time frame for all measures was the 10 days preceding the assessment. 
The IIEF is a self-rated 15-item instrument to assess sexual function in five functional domains: 
erection, orgasm, desire, intercourse satisfaction and overall satisfaction. Questions are anchored on a 
5-point  scale  with  1  corresponding  to  “almost  never/never”  and  5  corresponding  to  “almost 
always/always”. A score of 0 means the absence of sexual activity, stimulation or  intercourse. The 
minimum  possible  total  score  is  5,  and  the  maximum  total  is  75.  The  changes  in  the  IIEF  scores 
quantified the magnitude of the response.  
The GLF inventory was developed to tape distress, well-being, functioning and life satisfaction and 
has been shown to be sensitive to changes and to discriminate well between efficacious treatments [46]. 
It is based on seven items of the Dupuy’s psychological general wellbeing index to measure wellbeing 
and distress [47], supplied with six items tapping general functioning and life satisfaction. Each item is 
rated on a 6-point Likert scale, with higher scores indicating better outcomes. In the present study the 
GLF was used as a self-evaluation measure of patient general wellbeing and functioning.  
The severity of depressive symptoms was assessed using the standard abridged form of the BDI. 
Each of its 13 categories of symptoms and attitudes scores from 0 (absence of the symptom) to 3 
(extreme severity of the symptom). The ranges of total scores are: 0-4, none or minimal, 5-7, mild,  
8-15, moderate; and 16 and over, severe depressive symptoms.  
The RGSES is a 10-item Likert scale with items answered on a 4-point scale - from “strongly agree” 
to “strongly disagree”, with higher scores indicating higher self-esteem.  
The MSPSS was used as a self-report tool for assessing emotional help and the level of satisfaction 
with the social support obtained from family, friends and significant others. The scale includes 12 items, 
each of which refer to the people to whom the respondent would turn if he/she had problems of a 
personal, health or family nature, as well as financial and employment problems. Responses are scored 
on a 7-point scale from 1 (“completely disagree”) to 7 (“completely agree”). The MSPSS total score Int. J. Environ. Res. Public Health 2009, 6                 
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and three subscales scores are computed, with a higher score indicating a greater satisfaction with social 
support.  
For  the  entire  sample  (N  =  101),  internal  consistency  reliability,  as  measured  by  Cronbach’s   
coefficient, was satisfactory, specifically: 0.77 for the GLF; 0.80 for the BDI; 0.79 for the RGSES, and 
0.91 for the MSPSS. 
 
2.5. Statistical Analysis  
 
All analyses were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC, USA). Baseline 
demographic  characteristics  were  compared  using  descriptive  statistics  by  χ
2  and  Fisher exact tests 
(where cell sizes were <5). Mean scores and standard deviations (SDs) were computed and reported. 
The statistical significance of change from baseline to week 12 (Δ) was evaluated with two-tailed paired 
t-tests. Effect size is the primary outcome measure, and power for the study was calculated using effect 
size in each group. Expecting to find differences between the groups of effect size = 0.4 would clarify 
whether potential observed differences also merit clinical significance. Using a two-group analysis of 
effect  sizes  between  the  sildenafil  and  control  groups,  setting  alpha  at  0.05,  power  =  0.80  and  a  
two-tailed t-test, a minimum of 52 subjects per group is required. Thus, 52 patients per group met 
power requirements for these specific aims. 
Effect size (ES) for treatment efficacy of erectile dysfunction was calculated as the improvement in 
IIEF mean score for the sildenafil group minus the improvement in IIEF mean score of the control 
group over 12 weeks, divided by the standard deviation of the entire sample at baseline. ES for other 
variables studied was computed using the same equation. Following Cohen's classic demarcation [48], 
Middel  and  associates  [49]  showed  that  ES
 reflects  clinical  relevance.  An  ES  <0.20  indicates  "no 
change,"
 an  ES  ≥0.20  but  <0.50  indicates  "a  small  change,"  an  ES  ≥0.50  but  <0.80  indicates  "a 
moderate change," and an ES ≥0.80 indicates "a considerable change". We also use ES equal 0.5 SD as 
a universal measure of clinical significance [50].  
 
3. Results 
 
A  total  of  108  men  who  consented  to  participate  were  screened  and  randomized  to  sildenafil  
(n = 54) or standard treatment (n = 54). One hundred-one patients (94.4%; n = 50 for sildenafil and  
n = 51 for control group) completed all baseline and week 12 endpoint assessments. There were no 
statistically significant differences between treatment group completers in baseline demographics, except 
for a greater number of immigrants in the sildenafil-treated group (Table 1). Although the sildenafil-
assigned patients did differ significantly from the controls with regard to earlier age at first-time alcohol 
consumption (17.2 ±  3.4 vs. 21.3 ±  7.0 years; t = 3.75; P < 0.001) and age at first alcohol binge  
(20.5 ±  6.4 vs. 26.1 ±  8.6 years; t = 3.68, P < 0.001), the groups were similar in the variable of duration 
of harmful alcohol consumption. Likewise, the groups did not differ significantly in the number of prior 
inpatient detoxifications, average alcohol intake in the last six months, and the number of drinking days 
in the month preceding the study. Patients who withdrew (n = 7) were not associated with significantly 
different baseline demographic characteristics compared with completers. Int. J. Environ. Res. Public Health 2009, 6                 
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Table 2. Summary of results on the International Index of Erectile Function. 
Sexual function 
domain 
Sildenafil group (n = 50)  Control group (n = 51)  Effect 
size  Baseline  Endpoint  t-value   P-value   Baseline  Endpoint  t-value   P-value  
Total score  39.9(16.9)  56.7 (12.9)  7.23  <0.001  53.7 (10.8)  50.9(12.3)  1.90  0.64  1.25 
Erectile 
function 
15.9 (7.6)  23.2 (5.6)  6.79  <0.001  21.8 (5.3)  20.8 (5.7)  1.46  0.15  1.17 
Orgasmic 
function 
6.1 (3.1)  8.2 (2.1)  5.64  <0.001  8.0 (1.8)  7.4 (2.2)  2.27  0.03  1.01 
Sexual desire  6.0 (2.2)  7.3 (1.4)  5.11  <0.001  7.1 (1.5)  6.6 (1.4)  2.34  0.02  0.91 
Intercourse 
satisfaction 
7.1 (3.7)  10.3 (2.8)  5.51  <0.001  9.5 (2.4)  9.0 (2.5)  1.38  0.17  1.11 
Overall 
satisfaction 
4.7 (2.5)  7.6 (2.3)  8.35  <0.001  7.3 (1.9)  7.0 (2.0)  1.16  0.25  1.23 
Paired t-tests, two-tailed. 
 
Efficacy 
 
3.1. Sexual Function 
 
A statistically significant increase in the IIEF mean scores of each sexual function domain was noted 
among all sildenafil-treated patients (Table 2). In contrast, the mean scores of all the sexual function 
domains among the control patients decreased over the trial, and in orgasmic function and sexual desire 
domains this decline was found to be statistically significant (P < 0.05). ES ranged from 0.91 for sexual 
desire to 1.23 for overall satisfaction domain, and 1.25 for IIEF total score, indicating clinically relevant 
improvement according Cohen classical demarcation [48]. However, only ESs for sexual desire and 
overall satisfaction demonstrated clinical importance of the changes using a conservative measure of 
clinical improvement as 0.5SD [50].  
 
3.2. Depression  
 
Baseline levels of depression were generally unrelated to efficacy or treatment satisfaction. Both 
groups  demonstrated  a  statistically  significant  reduction  in  BDI  symptom  severity  scores,  with  the  
ES = 0.47 (Table 3).  
 
3.3. Psychosocial Functioning 
 
We observed a significant improvement in the GLF total scores as well as in the well-being and 
functioning subscale mean scores only in sildenafil-treated patients (all P < 0.001), but not in the control 
group. Correspondingly, ES values ranged from .44 for wellbeing to 0.57 for functioning domains, and 
0.63 for GLF total score, reflecting clinically important changes (all > 0.5DS).  
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Table 3. Summary of psychosocial outcomes. 
Outcome measure 
Sildenafil group (n = 50)  Control group (n = 51) 
Effect 
size  Baseline 
Changes 
from 
baseline to 
endpoint 
t-value  P-value  Baseline 
Changes 
from 
baseline 
to 
endpoint 
t-value  P-value 
General Life 
Functioning 
3.5 (0.7)  -0.5 (0.6)  5.04  <0.001  3.5 (0.6)  -0.09(0.5)  1.41  0.17  0.63 
 Well-being  3.4 (0.7)  -0.4 (0.7)  4.72  <0.001  3.6 (0.7)  -0.009 
(0.5) 
1.25  0.22  0.44 
 Functioning  3.5 (0.7)  -0.5 (0.7)  4.57  <0.001  3.5 (0.7)  -0.1 (0.6)  1.18  0.24  0.57 
Beck Depression 
Inventory 
10.5 (6.2)  4.9 (5.0)  6.93  <0.001  9.6 (6.1)  2.0 (4.8)  2.98  0.01  0.47 
General Self-Esteem 
Scale  
15.2 (3.7)  -2.4 (3.9)  4.27  <0.001  15.5(3.6)  -0.2 (3.4)  0.46  0.65  0.61 
MSPSS, total score  54.4 (8.9)  -3.2 (8.9)  2.52  0.02  51.7(14.2)  0.5 (9.3)  0.38  0.71  0.31 
 Family  17.8 (4.7)  -1.0 (4.4)  1.59  0.12  17.4 (6.0)  -0.2 (3.8)  0.30  0.77  0.15 
 Friends  16.8 (4.7)  -1.1 (3.0)  2.68  0.01  15.9 (5.9)  0.2 (3.4)  0.41  0.68  0.24 
 Significant others  19.8 (3.5)  -1.1 (3.8)  1.96  0.055  18.5 (4.6)  0.5 (3.5)  0.91  0.37  0.39 
* - Paired t-rests, two-tailed 
MSPSS, Multidimensional Scale of Perceived Social Support (45). 
 
3.4. Self-Esteem 
 
In  parallel  to  a  meaningful  depression reduction, the sense of self-esteem improved substantially 
among individuals of the sildenafil group (P < 0.001), while this remained at pretreatment levels among 
the controls (ES = 0.61).  
 
3.5. Social Support 
 
Similar  to  self-esteem,  from baseline to endpoint a significant improvement was observed in the 
perception of overall social support (P = 0.02) as well as support from friends (P = 0.01) and significant 
others (P = 0.05) in the sildenafil-treated patients, while it remained unchanged in the control group. 
However, ESs for these measures were low, 0.31 for overall support, 0.24 for friends' and 0.39 for 
significant others' support, did not reflecting clinical relevance.  
 
3.6. Adverse Effects 
 
Sildenafil  was  well  tolerated.  The  most  common  side-effect  was  headache,  reported  by  32%  of 
sildenafil-treated patients (n = 16). Only one patient reported dyspepsia (2%). All of these adverse 
effects were transient and mild in nature. No serious adverse events related to the study drug were 
reported. Int. J. Environ. Res. Public Health 2009, 6                 
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4. Discussion 
 
In our previous uncontrolled, open-label report [37] we indicated that sildenafil as an adjunct drug to 
standard  treatment  for  men  with  alcoholism  improved  sexual  function  and  overall  satisfaction  with 
intercourse in a clinically sound manner, as well as satisfaction with all specific domains of quality of 
life. The present open-label, controlled, multicenter study extends those preliminary findings showing 
that sildenafil treatment also significantly increased psychosocial outcomes of these patients such as 
wellbeing and functioning, self-esteem and the perception of social support as compared to a treatment 
as usual educational control group.  
The magnitude of improvements observed in this trial was comparable to that observed  in other 
clinical trials of sildenafil treatment for erectile dysfunction in depressive disorder, schizophrenia and 
PTSD [24,25,27] as well as in medical diseases and treatments [8,11,17,28-30,51]. Consistent with 
previous  studies,  the  efficacy  of  sildenafil  treatment  in  this  study  was  statistically  significant  and 
clinically  relevant  across  all  the  IIEF  domains,  under  condition  that  effect  sizes  were  interpreted 
according to Cohen's classic demarcation of 0.2, 0.5 and 0.8 referring to small, moderate and large  
ES's [48.49]. However, if ES equal 0.5 SD was taken into consideration as a universal measure of 
clinical  significance  [50],  only  changes  in  the  IIEF  domains  concerning  sexual  desire  and  overall 
satisfaction could be interpreted as clinically relevant. Regarding potential impact of between-group 
differences in IIEF scores at baseline on outcome scores at endpoint, such effect was reliably neutralized 
in effect size calculation using the denominator that the pooled baseline values of both groups. 
The effect of sildenafil on sexual functioning is not surprising, given that it is the primary target of its 
pharmacological action. This effect was noted in 98% of our patients, providing affirmative responses 
to global efficacy questions, concerning treatment-related improvement in erectile function and ability to 
perform  sexual  intercourse.  What  is  surprising  is  the  effects  of  sildenafil  on  virtually  all  the  
psychosocial outcomes.  
ED  is  a  complex  condition,  which  depends  upon  various  emotional,  societal,  and  relationship  
factors [52,53]. A recent qualitative study [54] described the impact of ED on subjective feelings of 40 
men, their expectations of sildenafil, and impact of treatment on themselves and their relationships. ED 
caused marked effects on self-esteem and their social relationships. Successful sildenafil treatment led to 
a significant improvement in wellbeing, confirming the beneficial effect on masculine self worth. In our 
previous study, we also showed that self-esteem was the primary mediating factor in the ED-quality of 
life relationship in 101 men suffering from AD and concomitant ED [55]. In line with data from several 
studies  [53,56-58]  we  found  that  among  those  who  responded  to  sildenafil  there  was  a  marked 
improvement not only in wellbeing and self-esteem, but also in general functioning, and perceived social 
support from friends and significant others.  
In accord with these changes, we observed a significant reduction in symptoms of depression in the 
sildenafil group. Noteworthy, depressive symptoms reduced also among the control subjects. Recall 
here  that  patients  with  severe  depression  (BDI  score  >15)  were  excluded  from  the  study.  This 
restriction in range of depressive scores might alter the sensitivity of the measure of depression. The 
improvement in BDI scores in both groups was no related to a nonspecific effect of the repeated visits 
with the research team.  Int. J. Environ. Res. Public Health 2009, 6                 
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Following Rosen and colleagues’ study [59] conclusion, we can suggest that psychosocial changes 
associated  with  ED  therapy  may  be  mediated  by  changes  in  sexual  function,  mood,  and  family 
relationships and/or, as we observed, by improvements in the senses of self-esteem and social support 
outcomes. However, the precise mechanisms by which sildenafil converts the beneficial effects on ED 
into the psychosocial domains require further studies.  
The main limitation of our study is its open-label nature and the lack of a placebo-control arm. It is 
unfortunate that no placebo group was used, since it is difficult to truly evaluate the clinical significance 
of change without the ability to compare it to placebo-induced change. Thus, a nonspecific, placebo 
effect with regard ED cannot be ruled out. However, such placebo effect seems unlikely, given the 
highly  significant  improvements  in  the  multiple  psychosocial  and  clinical  variables  achieved  for  a 
relatively short trial period. Moreover, these changes were not only statistically
 highly significant, but 
also appeared to be clinically relevant. Unlike a double-blind clinical trial, the open-label design is open 
for a clinician’s subjective bias during data collection and evaluation of study parameters, usually in 
favor of the efficacy of either experimental compound over comparator or vice versa. However, this is 
true mostly in respect to clinical impressions and assessments of symptoms, but not self-administered 
questionnaires, where the clinician’s impact on the outcome measurement is practically excluded.  A 
potential bias regarding qualification level of physicians is precluded because, to our knowledge, the 
clinicians of all participating centers were equivalently trained and had equal experience.  
The significant correlation between improvements in sexual functioning and psychosocial and clinical 
measures, we found in this study, seems to be genuine, and not artificial, implying a potential overlap 
between the underlying constructs. Unfortunately, because of a relatively short trial period we were not 
able to examine the effects of sildenafil on drinking patterns. This issue should be addressed in further 
longitudinal  study.  Nonetheless,  given  the  benefits  of  sildenafil  for  patients,  physicians  and  other 
healthcare professionals some authors argue that, with the provision of proper assessments, sildenafil 
should be made available as an over-the-counter medication [60]. 
In summary, this open-labeled comparative evaluation demonstrates that sildenafil addition was more 
effective for improving ED than standard treatment for alcoholism alone. There was little risk involved 
in  sildenafil  treatment,  since  potential  adverse  effects  of  sildenafil  were  limited only headache. The 
benefits  are  the confirmation of clinical efficacy and safe side-effect profile of sildenafil, as well as 
improvement  of  wellbeing,  mood  and  social  functioning  of  the  patients  with  AD.  The  information 
obtained in the study is valuable for both clinicians and policymakers to develop innovative therapeutic 
strategies for treatment of ED in men with alcohol dependence. 
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